Skip to content

Halozyme Therapeutics, Inc. (HALO) stock: revenue, earnings & dividend

Halozyme Therapeutics, Inc. (HALO, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener HALO · Nasdaq Pharma & Biotech US-CA

Key figures

Fiscal year
2025
Revenue
1.4 bn $
Revenue growth
37.6 %
Revenue growth 5y (p.a.)
39.2 %
Net income
317 m $
Net margin
22.7 %
Operating margin
33.6 %
Earnings per share (diluted)
2.56 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
2.53 bn $
Equity
48.8 m $
Equity ratio
1.9 %
Return on equity
649.2 %
Cash
134 m $
Operating cash flow
652 m $
Free cash flow
645 m $
Shares outstanding
114,010,000

History

Revenue by fiscal year

2016 147 m $
2017 317 m $
2018 152 m $
2019 196 m $
2020 268 m $
2021 443 m $
2022 660 m $
2023 829 m $
2024 1.02 bn $
2025 1.4 bn $

Net income by fiscal year

2016 -103.02 m $
2017 63 m $
2018 -80.33 m $
2019 -72.24 m $
2020 129 m $
2021 403 m $
2022 202 m $
2023 282 m $
2024 444 m $
2025 317 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20251.4 bn $317 m $2.56 $–652 m $
20241.02 bn $444 m $3.43 $–479 m $
2023829 m $282 m $2.10 $–389 m $
2022660 m $202 m $1.44 $–240 m $
2021443 m $403 m $2.74 $–299 m $
2020268 m $129 m $0.91 $–55.5 m $
2019196 m $-72.24 m $-0.50 $–-85.42 m $
2018152 m $-80.33 m $-0.56 $–-49.5 m $
2017317 m $63 m $0.45 $–134 m $
2016147 m $-103.02 m $-0.81 $–-50.38 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)